LAGUNA HILLS, Calif., May 31 /PRNewswire/ -- Symphony Medical, Inc., a developer of new non-destructive biologic therapies to treat atrial fibrillation and other cardiac abnormalities, announced today that veteran medical technology executive Raymond W. Cohen has been named chief executive officer and a member of the board of directors.
Cohen, 47, who has more than 25 years of leadership and entrepreneurial experience in health care, was for the past nine years the CEO of publicly-held Cardiac Science, Inc., a leading U.S. manufacturer of life-saving automatic public-access defibrillators that merged with Bothell, WA-based Quinton Cardiology Systems Inc. in 2005 and operates today under the name Cardiac Science Corporation, , where Cohen remains chairman of the board of directors.
Cohen also serves as a member of the board of directors of BioLife Solutions, Inc, a manufacturer of cryopreservation products used for human cell and tissue preservation, based in Owego, NY; and Syncroness, Inc., a privately-held contract engineering and product development firm based in Westminster, CO. He is also a member of the advisory board for the College of Osteopathic Medicine, Western University of Health Sciences in Pomona, CA.
When Cohen joined Cardiac Science in 1997 as its CEO, that company had no commercial products or revenue and only one issued patent. By 2004, under Cohen's leadership, it had grown to over $68 million in annual revenue, amassed an intellectual property portfolio of 77 issued patents and was ranked as the fourth fastest growing technology company in North America on the Deloitte & Touche Fast 500 list. In 2003, Cardiac Science was named Life Science Company of the Year by the American Electronics Association and Entrepreneurial Company of the Year by Frost and Sullivan in 2004.
"Ray Cohen is a natural leader and a successful entrepreneur with expertise in leading health care technology companies through the early stages of development and, ultimately, to commercial success," said Olav Bergheim, co-founder and chairman of the board of Symphony Medical as well as managing director of Orange County, CA-based Fjord Ventures. "Ray's passion, knowledge and entrepreneurial instincts will be invaluable to Symphony as we look to complete the development of our novel cardiac therapies and bring them to market."
Cohen is a graduate of State University of New York at Binghamton with a degree in business management and is an accredited public company director having completed the certification program at UCLA's Anderson Graduate School of Management. He lives with his family in Orange County, CA, and is active as a member of the Forum of Corporate Directors and the Young President's Organization.
About Symphony Medical, Inc.
Symphony Medical, founded in 2003, is a privately-held, venture-backed development stage company that develops proprietary biotherapeutic products and tools to address the unmet clinical needs of millions of patients suffering from cardiac disorders. The Company's products use proprietary biopolymers and cell therapies to treat patients with arrhythmias and other cardiac abnormalities through non-destructive (non-ablative and non-surgical) means. This is achieved, in part, by injecting biologic material directly into specific locations of the heart during either open chest surgery or via a minimally invasive procedure employing a catheter-based cardiac delivery system.
Symphony's initial product, which has advanced from pre-clinical to clinical stage testing, is a prophylactic method of preventing sustained post-operative atrial fibrillation, a common side affect of the approximately 500,000 coronary artery bypass grafting and cardiac valve replacement surgeries performed each year.
In a study that underscores the importance of addressing the problem of post-operative atrial fibrillation presented at the 27th annual Scientific Session of the Heart Rhythm Society, May 17-20, 2006 in Boston, researchers from Brigham and Women's Hospital, Boston, MA and University of Pennsylvania, Philadelphia, PA, examined coronary artery bypass grafting (CABG) patients who did not have any incidence of atrial fibrillation pre-operatively to determine if the development of post-CABG atrial fibrillation predicts a risk for being in atrial fibrillation at long term follow up. The authors concluded that patients who experience new atrial fibrillation post-CABG prior to discharge from the hospital have a high incidence of atrial fibrillation at three years if the atrial fibrillation fails to be successfully converted to normal prior to discharge. In contrast, transient post-CABG atrial fibrillation (whose atrial fibrillation spontaneously converted to normal prior to discharge) is not associated with any increased incidence of atrial fibrillation when compared to patients with no post-CABG atrial fibrillation.
For more information on Symphony Medical please visit our website at www.symphonymed.com or contact Matt Clawson at Allen & Caron Inc at 949-474-4300 or via email at email@example.com.
Symphony Medical Inc.